Paper25829397
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
Mok T and 19 others. Clin Cancer Res, 2015. Cited by 416 papers, by iCite.
Cite this record
ConductScience Library. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Papers, record 25829397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25829397
- Disease
- non-small cell lung carcinoma1,066 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
- PubMed
- Publication types
- Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| DNA Mutational Analysis | Major topic |
| DNA, Neoplasm | Major topic |
| Lung Neoplasms | Major topic |
| Aged | |
| Deoxycytidine | |
| Disease-Free Survival | |
| Double-Blind Method | |
| Erlotinib Hydrochloride | |
| Female | |
| Genes, erbB-1 | |
| Humans | |
| Intercalating Agents | |
| Kaplan-Meier Estimate | |
| Male | |
| Middle Aged | |
| Mutation | |
| Platinum Compounds | |
| Treatment Outcome | |
| Gemcitabine |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03090815 | Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma | Background | ClinicalTrials.gov | |
| NCT04358562 | Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib | Results | ClinicalTrials.gov |
Cited by269
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 416 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42098393 | Liquid Biopsy in Primary CNS Tumors: Bridging Biology, Technology, and Clinical Care. | Mol Diagn Ther | 2026 | https://conductscience.org/library/papers/42098393 | PubMed |
| 41890329 | Bibliometric Analysis of Randomized Clinical Trials in the Philippines. | Acta Med Philipp | 2026 | https://conductscience.org/library/papers/41890329 | PubMed |
| 41677996 | The progress of biomarkers detection to lung cancer. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41677996 | PubMed |
| 41519536 | Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact. | J Thorac Oncol | 2026 | https://conductscience.org/library/papers/41519536 | PubMed |
| 40830279 | Oncogene-driven lung cancer in the era of radiogenomics: current evidence and future developments. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40830279 | PubMed |
| 40825939 | The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis. | Biomark Med | 2025 | https://conductscience.org/library/papers/40825939 | PubMed |
| 40776748 | Comprehensive genetic profiling using tissue and blood in locally advanced tumors. | Oncol Rep | 2025 | https://conductscience.org/library/papers/40776748 | PubMed |
| 40465842 | Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40465842 | PubMed |
| 40299851 | Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer. | Cancer Discov | 2025 | https://conductscience.org/library/papers/40299851 | PubMed |
| 40219616 | Liquid Biopsy in Solid Tumours: An Overview. | Cytopathology | 2025 | https://conductscience.org/library/papers/40219616 | PubMed |
| 40144458 | The prospects and limitations of liquid biopsy utilization for clinical practice in Taiwan. | J Liq Biopsy | 2025 | https://conductscience.org/library/papers/40144458 | PubMed |
| 40065316 | Efficacy of liquid biopsy for genetic mutations determination in non-small cell lung cancer: a systematic review on literatures. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40065316 | PubMed |
| 39844103 | Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis. | BMC Cancer | 2025 | https://conductscience.org/library/papers/39844103 | PubMed |
| 39830755 | Can circulating tumor DNA guide treatment de-escalation in metastatic lung adenocarcinoma harboring actionable genomic alterations? | Transl Lung Cancer Res | 2024 | https://conductscience.org/library/papers/39830755 | PubMed |
| 39769431 | The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39769431 | PubMed |
| 39353410 | A Comprehensive Review of Epidermal Growth Factor Receptor Mutation Abundance in Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors. | Oncol Res Treat | 2024 | https://conductscience.org/library/papers/39353410 | PubMed |
| 39317868 | Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy. | Clin Transl Oncol | 2025 | https://conductscience.org/library/papers/39317868 | PubMed |
| 39239557 | Clinical applications of circulating biomarkers in non-small cell lung cancer. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/39239557 | PubMed |
| 39231375 | Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer. | JCO Precis Oncol | 2024 | https://conductscience.org/library/papers/39231375 | PubMed |
| 39184861 | Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/39184861 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CATEQUENTINIB | CHEMBL4303201 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL4303201 | ChEMBL |
| GEFITINIB | CHEMBL939 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL939 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25829397
GET https://conductscience.org/api/papers/v1/25829397/cited_by?page=2